% | $
Quotes you view appear here for quick access.

Antares Pharma Inc. Message Board

  • mofisher22 mofisher22 Apr 28, 2013 9:34 PM Flag

    The 2 day chart says it all, and Ali hit a grand slam, now for the trifecta,

    we need James, Jr., and Scott to resume their informative articles, would be perfect timing, and probably get a lot of new audience since last year. How about one, or both, of you to step up with some updated info. glta

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I believe this time the move higher is sustainable. I just read the "Comments" to the latest SA article. In the latest comment someone called Jorge posts that he decided to get long ATRS and was asking Ali whether to pull the trigger tomorrow or later

    • Mo, I think we'd be much better off if Ali was the only source for SA articles. James & Scott have a reputation more of traders then investors.

      I was comparing ATRS's valuation to PCRX tonight & it reinforces my belief that ATRS will have a billion plus valuation & a $10 stock price at this time next year. Everyone including me wants the double tomorrow, but if you can hold on then a 100% gain in a year is not bad.

      • 2 Replies to whogo70
      • The financial profile is nothing like ATRS either. What is the point you are trying to make. All ears?

      • ATRS is ATRS not any other stock. They have nothing in common.

        Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures pharmaceutical products for use in hospitals and ambulatory surgery centers worldwide. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company markets EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic, indicated for administration into the surgical site to produce postsurgical analgesia; and DepoCyt(e), a liposomal formulation of the chemotherapeutic agent cytarabine indicated for the intrathecal treatment of lymphomatous meningitis, a cancer of the immune system. Its product pipeline comprise EXPAREL that has completed Phase II clinical trials for postsurgical analgesia-nerve block administration; DepoNSAID, which is in preclinical trials for the relief of acute pain; and DepoMethotrexate that is in preclinical trials for the treatment of rheumatoid arthritis and oncology, as well as Bupivacaine Liposome Injectable Suspension for veterinary postsurgical analgesia. Pacira Pharmaceuticals, Inc. has a development and commercialization agreement, and related supply agreement with Aratana Therapeutics, Inc. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.

1.00-0.02(-1.96%)Jul 29 4:00 PMEDT